Financial News · Live Terminal

Page 179 of 741

AbbVie Submits Application for Upadacitinib as Alopecia Areata Treatment to FDA

AbbVie (ABBV) submitted to the US Food and Drug Administration an application for upadacitinib's new indication as treatment for adult and adolescent patients with severe alopecia areata, the company said Tuesday.The company said it used data from a phase 3 trial of upadacitinib, also known as Rinvoq, to support the application. The trial met its primary endpoint of a severity of alopecia tool score of less than or equal to 20 at week 24, AbbVie said.Upadacitinib's safety profile in the trial was also consistent with previously announced study results, the company added.Price: $197.37, Change: $-0.03, Percent Change: -0.02%

$ABBV

Australia2d ago

Morgan Stanley Adjusts Public Service Enterprise Price Target to $94 From $90, Maintains Overweight Rating

Public Service Enterprise Group (PEG) has an average rating of overweight and mean price target of $91.38, according to analysts polled by FactSet.Price: $80.39, Change: $+0.18, Percent Change: +0.22%

$PEG

Australia2d ago

Honeywell International Sets June 29 Target for Aerospace Spin-Off Completion

Honeywell International (HON) said Tuesday that it expects to complete the spin-off of its aerospace business on June 29 and has named the incoming board for the standalone Honeywell Aerospace.The spin-off will create one of the largest publicly listed pure-play aerospace and defense companies, with Honeywell aiming to unlock value and sharpen its strategic focus, it said.Honeywell's new 11-member board will be led by former Eaton (ETN) chief executive officer Craig Arnold as independent chair, with Honeywell Aerospace CEO Jim Currier also joining the board alongside other industry leaders, the company added.Price: $212.91, Change: $+0.86, Percent Change: +0.41%

$ETN$HON

Showing 3561-3580 of 14802

Financial News · Live Terminal

AbbVie Submits Application for Upadacitinib as Alopecia Areata Treatment to FDA

Morgan Stanley Adjusts Public Service Enterprise Price Target to $94 From $90, Maintains Overweight Rating

Honeywell International Sets June 29 Target for Aerospace Spin-Off Completion

AbbVie Submits Application for Upadacitinib as Alopecia Areata Treatment to FDA

Morgan Stanley Adjusts Public Service Enterprise Price Target to $94 From $90, Maintains Overweight Rating

Honeywell International Sets June 29 Target for Aerospace Spin-Off Completion

Morgan Stanley Lifts Old Dominion Freight Line Price Target to $215 From $209, Maintains Overweight Rating

Orlen Says Saudi Aramco Oil Deliveries On Track Amid Middle East Conflict

Research Alert: Wso: A Q1 Earnings Beat Over Subdued Expectations

Research Alert: Cvlt Exceeds Expectations On Saas Momentum And Strong Free Cash Flow

Morgan Stanley Adjusts Devon Energy Price Target to $59 From $46, Maintains Overweight Rating

Canada, U.S. Trade Agreement Likely, Eventually, says Nomura

Jiuyuan Genetic Biopharmaceutical Gets China Nod for Weight Management Drug Trial

Research Alert: Openai Internal Target Miss Worrisome For The Ai Ecosystem

Research Alert: Cvlt Exceeds Expectations On Saas Momentum And Strong Free Cash Flow

Morgan Stanley Adjusts FirstEnergy Price Target to $54 From $53, Maintains Overweight Rating

JPMorgan Chase Chosen as First Global Banking Partner of Olympic Games

Morgan Stanley Adjusts Price Target on Paychex to $107 From $123, Maintains Equalweight Rating

Morgan Stanley Adjusts Price Target on Kimco Realty to $24 From $23.50, Maintains Equalweight Rating

BYD's Q1 Profit Slips 55%

ARC Resources Downgraded to Market Perform at BMO Following Shell's Acquisition Offer; Price Target at C$32.00

TSX Now Down Near 50 Pts, Was Down More Double That at the Open; But Adding to 3 Straight Days of Losses

Morgan Stanley Lifts Corpay Price Target to $390 From $379, Maintains Overweight Rating